Integrative transcriptomics identified conserved central-peripheral signatures in PD and five hub genes are candidate biomarkers/therapeutic targets, offering a systems-level framework for disease mechanisms and independent cohort validation.
Ehsan Lotfi, Arsh Ketabforoush, Fereshteh Azeditehrani et al.· Bioinformatics and Biology I...· 0 citations
Brain cancers are among the most aggressive malignancies associated with significant global morbidity and mortality. Cancer immunotherapy has emerged as a promising novel approach for the treatment of brain cancer through regulating the PD-1/PD-L1 signaling and disrupting tumor immune escape. Several targeted therapies...
Reihane Behnam-Rassouli, Farzaneh Entezari, Majid Ghorbanzadeh et al.· Iranian Journal of Basic Med...· 0 citations
Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, CTLA-4, and LAG-3 have transformed cancer therapy, but resistance limits durable benefit. This integrative review summarizes primary, adaptive, and acquired resistance driven by tumor-intrinsic defects, suppressive tumor microenvironmental programs, and host-re...
Ehsan Lotfi, F. Golab· Cancer Investigation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.